Breakdown JNJ (Johnson & Johnson) Tax Rate Trend Fair Price
NYQ Β· Healthcare Β· Drug Manufacturers - General
$266.32
+0.74 (+0.28%)
JNJ Interactive Price Chart & Trading Signals
JNJ Stock Snapshot β Valuation, Risk & Technical Signals
JNJ Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$641.80B
P/E Ratio
30.86
Forward P/E
21.51
PEG Ratio
2.78
P/B Ratio
7.55
EPS
$8.63
Dividend Yield
2.01%
52W Range
$173.33 β $281.07
Beta
0.23
Volume
4.7M
ROE
25.7%
Profit Margin
21.5%
Revenue Growth
6.6%
Gross Margin
68.1%
EV/EBITDA
19.21
Analyst Target
$277.91
The trailing price-to-earnings ratio stands at 30.9x. Forward P/E of 21.5x implies earnings expansion expected. Price-to-book is 7.55x. EV/EBITDA sits at 19.21x. Market capitalization is $641.80B. Revenue is growing at 6.6% on a trailing basis. Earnings are compressing at -0.9%. Profit margins are 21.5%. Return on equity is 25.7%. Beta of 0.23 indicates defensive profile.
Analyst Consensus
Recommendation
Buy
Low Target
$190.00
Mean Target
$277.91
High Target
$320.00
Based on 22 analysts
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
JNJ Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
Quality-focused portfoliosWatch out for
Premium valuation, Earnings declineData confidence
HighJohnson & Johnson (JNJ) trades above our multi-model fair value estimate of $112.85 by approximately 57.6%. Trailing P/E: 30.9x. Profitability signals include profit margin of 21.5% and return on equity of 25.7%. Recent growth metrics show revenue growth of 6.6% and earnings growth of -0.9%. Risk profile: defensive beta of 0.23. Consensus: buy.
JNJ Deep Dive Analysis
Valuation
Overvalued
P/E 30.9x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 6.6%
Revenue is outpacing the market.
Risk
Low
Beta 0.23
Movement is likely to track the broader market.
Valuation Snapshot
Johnson & Johnson (JNJ) trades above our multi-model fair value estimate of $112.85 by approximately 57.6%. The trailing price-to-earnings ratio stands at 30.9x. Forward P/E of 21.5x suggests earnings compression ahead. Price-to-sales is 6.6x. Price-to-book is 7.5x. EV/EBITDA sits at 19.2x. Market capitalization is $641.80B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 6.6% on a trailing basis. Earnings are compressing at -0.9%. Profit margins are 21.5%. Return on equity is 25.7%. Return on assets is 8.6%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.23 indicates defensive profile. Net debt position is $28.28B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $277.91 implies 4.4% upside. Target range spans $190.00 to $320.00. 22 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
Strong profitability metrics may appeal to quality-focused portfolios.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, market cap: Yahoo Finance (delayed ~5 min)
- P/E, EPS, revenue, debt: Yahoo Finance fundamentals
- Analyst targets: Yahoo Finance consensus (may lag)
- Insider trades: SEC EDGAR Form 4 filings
QuantSoar Model (Derived)
- Fair Value: 7-model consensus (DCF, Graham, P/E, P/S, DDM, EV/EBITDA, Div Yield) β trimmed inverse-variance weighted
- Margin of Safety = (Fair Value β Live Price) / Live Price Γ 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation(Β±25) + Whale(Β±10) + Macro(Β±10) + Technical(Β±10). Analyst consensus shown separately.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
JNJ Overvalued
Johnson & Johnson (JNJ) trades above our multi-model fair value estimate of $112.85 by approximately 57.6%.
Frequently Asked Questions
ValuationIs JNJ stock overvalued right now?
ValuationWhat is JNJ fair value based on current fundamentals?
RiskHow risky is JNJ compared with other stocks?
GrowthIs JNJ still growing?
AnalystWhat do analysts think about JNJ?
DividendDoes JNJ pay a dividend?
CatalystWhat could change the investment case for JNJ?
Related Stocks
PFE
Peer stock in Healthcare
View analysis βMRK
Peer stock in Healthcare
View analysis βABBV
Peer stock in Healthcare
View analysis βJNJ vs PFE
Side-by-side valuation, risk, and growth comparison
Compare βJNJ vs MRK
Side-by-side valuation, risk, and growth comparison
Compare βHealthcare
Explore top stocks in this sector
Explore sector β
About the Author
Phasakorn Traklang (Peach) β Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.